The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Breen, who has been with the company since 2018 and has served as its COO since 2023, will succeed Thomas Caulfield in the top role. Prior to joining GlobalFoundries, Breen held a senior executive ...

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Frick succeeds Model e Chief Operating Officer Marin Gjaja, who has been named Ford's new chief strategy officer and will ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...

GlobalFoundries said its board of directors has appointed Thomas Caulfield as executive chairman and Tim Breen as chief executive. The Malta, N.Y. technology company said Caulfield succeeds Ahmed ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

Total Q4 sales GBP 8.12B up 1% AER; up 4% CER. Vaccines sales down 12%. Specialty Medicines sales up 17%. HIV sales up 14%. Oncology up 72%.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...